SAN MARINO, Calif.--(BUSINESS WIRE)--Viral Genetics, Inc. (Other OTC:VRAL), a biotechnology company that discovers and develops immune-based therapies, today announced it has completed its acquisition of V-Clip Pharmaceuticals, Inc. (“V-Clip”). Viral Genetics has exercised its option to obtain the remaining 56 percent of V-Clip it did not already own. Upon closing, Viral Genetics will own 100 percent of V-Clip and V-Clip’s exclusive worldwide rights to patent applications developed by Dr. M. Karen Newell, PhD, of the University of Colorado at Colorado Springs. The acquisition is in response to the study team’s success in proving the viability of Newell’s mechanism of action, which is now being used to further Viral Genetics’ research in HIV/AIDS and other immune based diseases. Through the V-Clip merger Viral Genetics has not only added to the company’s intellectual property portfolio but has considerably expanded its IP in AIDS and an array of other diseases.
